1. T0901317, an LXR agonist, augments PKA-induced vascular cell calcification
- Author
-
Hsu, Jeffrey J., Lu, Jinxiu, Huang, Michael S., Geng, Yifan, Sage, Andrew P., Bradley, Michelle N., Tontonoz, Peter, Demer, Linda L., and Tintut, Yin
- Subjects
LIGANDS (Biochemistry) ,NUCLEAR receptors (Biochemistry) ,ATHEROSCLEROSIS treatment ,PROTEIN kinases ,CALCIFICATION ,ALKALINE phosphatase ,THERAPEUTICS - Abstract
Abstract: We examined the effect of liver X receptor (LXR) agonists on vascular calcification, prevalent in atherosclerotic lesions. T0901317, an LXR agonist, augmented protein kinase A (PKA)-induced mineralization and alkaline phosphatase (ALP) activity in aortic smooth muscle cells isolated from wild-type, but not from Lxrβ
−/− mice. A six-hour T0901317 treatment augmented the PKA-induced expression of the phosphate transporter Pit-1, a positive regulator of mineralization, suggesting a direct role. A ten-day T0901317 treatment attenuated PKA-induced expression of mineralization inhibitors, osteopontin and ectonucleotide pyrophosphatase/phosphodiesterase-1, suggesting an indirect role. The effects of T0901317 were attenuated by inhibition of ALP, Pit-1 and Rho-associated kinase, but not by inhibition of PKA. These results suggest that T0901317-augmented mineralization occurs downstream of PKA, involving both direct and indirect LXR-mediated pathways. [Copyright &y& Elsevier]- Published
- 2009
- Full Text
- View/download PDF